Bellerophon Therapeutics (NSDQ:BLPH) said yesterday that it inked a $3 million direct offering of common stock with a single, unnamed institutional investor. The offering is expected to close by the beginning of next week. Warren, N.J.-based Bellerophon plans to issue 2 million registered shares of common stock at $1.50 apiece in connection with the offering. […]
Bellerophon Therapeutics
Bellerophon touts effects of inhaled nitric oxide in pulmonary arterial hypertension
Bellerophon Therapeutics (NSDQ:BLPH) presented data for its INOpulse nitric oxide device in patients with pulmonary arterial hypertension at the International Society of Heart and Lung Transplantation’s annual meeting. Researchers studied the effects of pulsed inhaled nitric oxide, delivered by the INOpulse device in 10 patients with pulmonary arterial hypertension both before and after exercise. The […]
Bellerophon plunges on failed cardiac implant trial
Bellerophon Therapeutics (NSDQ:BLPH) said today that its bioabsorbable cardiac matrix failed to meet both the primary and secondary endpoints in a 303-patient clinical trial, sending its share price down nearly -63% today. BCM is a liquid medical device injected into the coronary artery leading to the damaged area of a heart, and is designed for use after […]